Table 1.
Patient background and follow‐up characteristics
| Nonoperated during follow‐up | Operated during follow‐up | ||
|---|---|---|---|
| n = 90 | n = 77 | p | |
| Gender, female, n (%) | 54 (60.0) | 49 (63.6) | .64 |
| Age, median (Q1–Q3) (year) | 48.6 (39–59) | 45.3 (35–53) | .027 |
| Smokers, n (%) | |||
| No | 74 (85.1) | 62 (83.8) | .83 |
| Current | 13 (14.9) | 12 (16.2) | |
| AR, n (%) | |||
| No | 40 (44.4) | 32 (42.1) | .88 |
| Yes | 50 (55.6) | 44 (57.9) | |
| Asthma, n (%) | |||
| No | 3 (3.4) | 2 (2.6) | 1.0 |
| Yes | 86 (96.6) | 75 (97.4) | |
| Duration of symptoms (years), median (Q1‐Q3) | 15 (8.5–24.5) | 12 (5–23) | .40 |
| ≥ 1 OCS course/years, at baseline, n (%) | |||
| No | 46 (53.5) | 29 (39.7) | .11 |
| Yes | 40 (46.5) | 44 (60.3) | |
| ≥4 Antibiotic courses/years, at baseline, n (%) | |||
| No | 49 (62.8) | 37 (56.9) | .50 |
| Yes | 29 (37.2) | 28 (43.1) | |
| NP eosinophilia, at baseline, n (%) | |||
| <30% | 12 (34.3) | 7 (16.3) | .11 |
| ≥30% | 23 (65.7) | 36 (83.7) | |
| Endoscopic NP score, at baseline, median (Q1–Q3) | 5 (3.75‐6) | 5.5 (4–6) | .11 |
| Total LM score of sinus CT scans, at baseline, median (Q1–Q3) | 17.5 (14–21) | 20 (15–23) | .056 |
| Number of previous ESS, median (Q1–Q3) | 2 (0‐3.25) | 2 (0–4) | .76 |
| Baseline ESS within 1 year after the first consultation, n (%) | |||
| No | 17 (18.9) | 12 (15.6) | .68 |
| Yes | 73 (81.1) | 65 (84.4) | |
| Baseline total ethmoidectomy within 1 year after the first consultation, n (%) | |||
| No | 66 (76.7) | 64 (87.7) | .099 |
| Yes | 20 (23.3) | 9 (12.3) | |
| Baseline start with ATAD, n (%) | 51 (56.7) | 43 (59.7) | .75 |
| Follow‐up time (years), median (Q1–Q3) | 6.1 (4.2–10.6) | 7.9 (4.9–11.4) | .049 |
| Time until the first ESS (years), during follow‐up, median (Q1–Q3) a | ‐ | 3 (1.5–4.5) | ‐ |
| Revision ESS within 5 years after baseline surgery b | |||
| No | 59 (100) | 5 (7.7) | < .001 |
| Yes | 0 (0) | 60 (92.3) | |
| Number of ESS during the follow‐up | |||
| 0 | 90 (100) | 0 (0) | < .001 |
| 1 | 0 (0) | 52 (67.5) | |
| 2 | 0 (0) | 20 (26.0) | |
| ≥3 | 0 (0) | 5 (6.5) | |
| Start with biological therapy during follow‐up | 3 (3.3) | 2 (2.6) | 1.0 |
| Number of OCS courses/years during the follow‐up, n (%) | |||
| 0 | 34 (44.2) | 13 (21.0) | .002 |
| ≥1–2 | 20 (26.0) | 33 (53.2) | |
| 3 and/or continuous OCS | 23 (29.9) | 16 (25.8) | |
| No. of antibiotic courses/years during 2016–2019, median (Q1–Q3) | 0.5 (0–1.25) | 1.0 (0.5–2) | < .001 |
Note: p values by Fisher's exact test (dichotomous variables) or Kruskal–Wallis and Mann–Whitney U test (continuous variables). Q1 = 25% percentile, Q3 = 75% percentile. Bold values denote statistical significance at the p < .05 level.
Abrreviations: AD, aspirin desensitization; AR, allergic rhinitis; ASA, aspirin; ATAD, ASA treatment after desensitization; CRS, chronic rhinosinusitis; N‐ERD, patient‐reported NSAID‐exacerbated respiratory disease; NP, nasal polyps; OCS, oral corticosteroid.
a
All patients were included.
b
Only the group which underwent baseline ESS within 1 year after the baseline consultation.